How should a named comparison be read?
A named comparison can tell you which providers deserve a first enquiry, what each is built for, and where the known difficulties sit. It cannot promise you an account. In this category acceptance is per merchant: the same provider approves one pharmacy and declines another on product mix, volumes, history and the quality of the file. So every entry below carries a stance line, recording what the provider's published terms and credible reporting indicate at 27 July 2026. And every verdict ends at the same point: the one-line filter, in writing, for your own pharmacy. Where this article and a provider's written answer diverge, the written answer governs.
We assess each provider against the ten criteria from the buyer's guide, compressed to the four that separate providers most in practice: pharmacy stance, recurring-billing quality, platform fit, and the terms on reserves and exit. The disclosure from the standfirst bears repeating in the body. This site's publisher builds pharmacy checkouts and holds partner or integration relationships with certain providers named, including Mollie. No provider paid to appear, and the market-wide guidance — filter first, contract against the criteria — stays provider-agnostic.
What does the field look like?
| Provider or tier | Type | Pharmacy stance (as published or reported, Jul 2026) | Best suited to |
|---|---|---|---|
| Mollie | European PSP, UK-active | Onboards pharmacies with enhanced documentation, with category approved per merchant at registration | Independent online pharmacies, and Shopify or custom builds seeking a modern stack |
| PayPal | Wallet and PSP | Pharmaceuticals within pre-approval categories under its Acceptable Use Policy | A conversion-lifting wallet alongside a card backbone, following pre-approval |
| Stripe | Global PSP | Restricted-category terms, requiring explicit support, with self-serve unsuitable | Only with written category acceptance, failing which it becomes the case study |
| Worldpay, Barclaycard and peers | Traditional UK acquirers | Board pharmacies through full underwriting, with long in-store pharmacy heritage | Established pharmacies seeking bank-grade acquiring across in-store and online |
| High-risk specialists (Total Processing, Trust Payments, emerchantpay among others) | Specialist acquirers and PSPs | Market openly to regulated sectors including pharmacy, with acceptance per file | Higher-risk mixes, subscription-heavy models, and merchants declined upstream |
| Enterprise platforms (Checkout.com among others) | Enterprise PSP and acquirer | Regulated verticals considered case by case at commercial scale | Scaled operators holding volume sufficient to negotiate |
What of Mollie?
Mollie is an Amsterdam-founded PSP operating across the UK and more than thirty European countries. It holds PCI DSS Level 1 and supports more than thirty-five payment methods across cards, wallets and local European options. It prices per transaction with no monthly fees or long-term contracts, settles daily, and provides native tooling for the recurring payments treatment plans depend on.
It earns its place on this list because of a stance shift. As of late 2025 into 2026, Mollie is reported and observed to onboard UK pharmacies, with enhanced supporting documentation required during compliance checks: registration, superintendent details and website review. That is the underwriting file the high-risk analysis recommends preparing. Its user terms spell out the mechanics. Activities are approved at registration, a prohibited list applies, and Mollie keeps the discretion to decline risk it does not want to hold. In other words, acceptance is genuine and per merchant — exactly as the filter assumes.
Its strengths for pharmacy use: clean integrations for Shopify, WooCommerce and custom builds, which matters doubly given the Shopify native-payments constraint; genuinely broad European payment-method coverage if you serve beyond cards; and onboarding that, with the file prepared, runs in days rather than the weeks acquirer underwriting requires.
Two things deserve attention. This is a PSP relationship, not your own acquiring account, so portfolio risk policy applies. Ask the freeze-protocol and token-portability questions from the criteria guide before you depend on it, not after. And approval covers the mix you declared, so a later expansion into higher-risk lines goes back through compliance — declared, not discovered. The verdict, in mid-2026: Mollie is the strongest first shortlist entry for a typical independent UK online pharmacy, subject to the disclosure above, which invites you to apply the filter to this assessment as well.
What of PayPal?
PayPal at a pharmacy checkout is two different products behind one button. As a wallet, it measurably improves conversion among customers who trust it more than entering card details. That segment skews towards exactly the cautious first-time patient a new pharmacy wants to convert. As primary rails, it is the wrong instrument. Its Acceptable Use Policy places pharmaceutical sales among the activities requiring pre-approval, and operating without that approval is volunteering for the account-limitation process with your float inside it.
So the right sequence runs: card backbone first, with a provider from this list. Then PayPal's pre-approval route, applied for with GPhC registration, certification and a compliant site evidenced. Then the button, added as a conversion feature rather than a foundation. Approved and positioned like that, it earns its place. Treated as the entire payment stack, it concentrates every risk described in this cluster within a single non-acquiring relationship. One operational note: PayPal disputes run through its own resolution machinery alongside card chargebacks. The dispute-design habits from the criteria guide — recognisable descriptors, dispatch evidence, straightforward cancellation — apply with an extra venue attached.
What of Stripe, handled honestly?
Stripe belongs in this article because every founder asks about it, and it deserves an honest paragraph rather than a dismissal. It is excellent payments technology, with the developer experience the rest of the market imitates. But its restricted-business terms have historically treated pharmaceuticals as a category requiring explicit support — which its instant self-serve onboarding does not provide.
That mismatch, not hostility, explains why Stripe features so prominently in the sector's account-loss stories. Undeclared pharmacies board in minutes, trade for months, then meet the risk team at volume — the sequence the companion analysis identifies as the characteristic failure. The honest position: if you want Stripe, ask Stripe, in writing, before building, whether your registered pharmacy at your mix is supportable. Certain regulated-healthcare merchants do operate on the platform under explicit arrangements, and with one secured the technology is excellent. If the answer is negative or absent, that is the answer. Routing around it through a softened business description is the single course this cluster prohibits. The verdict: written acceptance makes it viable; anything less makes it the case study.
What of the traditional acquirer route?
The UK's established acquirers — Worldpay and Barclaycard Payments are the familiar names among several — have banked bricks-and-mortar pharmacy for decades. The terminal on most dispensary counters answers to one of them. For card-not-present pharmacy they remain fully available through the front door: full underwriting, the scheme registrations the category requires, and timelines measured in weeks.
What that buys is substance rather than speed: your own account with an FCA-supervised institution of scale, contracted terms, and a counterparty whose risk decision was individual rather than algorithmic. What it costs: onboarding friction, generally less modern developer tooling than the PSP tier provides, and pricing that rewards negotiation and volume rather than defaulting to reasonable. The verdict: this is the natural home for established pharmacies unifying in-store and online acquiring, for operators who value bank-grade stability above stack elegance, and for any merchant whose volumes justify negotiating interchange-plus properly. As a first rail for a small launch it is over-engineered — that is the PSP tier's job.
What of the high-risk specialists?
Between the mainstream and the offshore market sits a legitimate tier the criteria guide anticipated: onshore, FCA-supervised acquirers and PSPs that market openly to regulated and higher-risk sectors, pharmacy named among them. Names UK operators will encounter include Total Processing, Trust Payments and emerchantpay, among others.
Their economics are candid about the category: pricing above mainstream retail, reserves in most cases, and genuine underwriting. In exchange you get a counterparty whose business is precisely merchants of this kind, with dispute tooling, MIT-competent gateways and account management accustomed to regulated files. Treat their pharmacy marketing as an invitation rather than a promise. Acceptance still turns on the file, and the filter, the ten written questions and the contract-clause review apply at full strength. Reserves and exit terms deserve particular attention, because specialist contracts vary more widely than mainstream ones.
The verdict: this tier suits product mixes the PSPs decline, including controlled-drug-adjacent lines and aggressive subscription models, plus merchants rebuilding after a termination. It also makes a sensible second relationship for continuity once a primary rail is stable. The line to watch is jurisdictional. Onshore and supervised is a tier; offshore and guaranteed is the trap. No shortage of brokers will try to walk you from one to the other.
What of the enterprise platforms?
At scale the conversation changes vendors. Enterprise platforms — Checkout.com is the name most often encountered from London — combine PSP-grade technology with acquiring, and treat regulated verticals as commercial negotiations rather than categories to be checked. For a pharmacy group or a scaled digital-health operator the proposition is genuine: negotiated interchange-plus pricing, dedicated risk and account teams, multi-entity and multi-currency structures, and engineering support for a stack that by then includes subscriptions, wallets and possibly in-store acceptance.
The gate is volume. These relationships are secured with forecasts in the millions, and the diligence is the same criteria examined more closely. Exit and token portability matter more, not less, once a migration would involve seven figures of stored mandates. The verdict: not a first rail, but the destination negotiation for operators whose growth has earned it — ideally conducted with genuine statements from two existing providers in hand.
What has been excluded, and why?
Three absences are deliberate. Buy now, pay later is excluded because consumer credit at a medicines checkout raises affordability and ethical questions this site argues separately, and because the major providers' own category rules are restrictive around healthcare. That is principle, not oversight. The offshore high-risk brokers are excluded for the reasons this cluster has already set out: an ecosystem whose defining trait is serving the declined has no place on a registered pharmacy's shortlist. Crypto-settlement gateways are excluded on the same reasoning. When a proposition from any of the three arrives dressed as innovation, the criteria guide's section on disqualifying responses has already written the reply.
What does the file which secures approval contain?
Every provider on this list, from Mollie's enhanced-documentation onboarding through to a specialist's full underwriting, is reading versions of a single file. Build it once and submit it everywhere.
The core pack: incorporation documents with directors and beneficial owners identifiable. The GPhC premises registration and superintendent details, presented prominently — these are the artefacts that reclassify you from anonymous category risk into a named regulated business. The product list with legal classifications stated across GSL, P and POM, with any controlled-drug lines flagged rather than obscured; an underwriter who discovers them later has discovered a misrepresentation. The prescribing model in one paragraph a banker can follow: who prescribes, how patients are assessed, and where the remote prescribing standards are satisfied. Certification status, whether held or in progress. Realistic volume and average-order forecasts you intend to stay within. Bank details and the identity checks payment law requires. And the website itself, complete enough to be read as the underwriting artefact it is, with terms, privacy notice, refund policy and the prescription flow all visible.
Provider-specific additions then attach. Mollie's compliance checks need the enhanced documentation supplied during application. PayPal's route runs through its pre-approval process with the AUP category named. The specialists and acquirers add financials and, for young companies, the personal-guarantee discussion the criteria guide recommends negotiating rather than accepting.
Two habits keep an approval alive. Monitor providers' policy pages the way you monitor GPhC updates — the stances recorded here are dated for a reason. And route every product-mix expansion through a declared approval before launch. The account that fails is almost never the one that was refused. It is the one that quietly outgrew what it was approved for.
What are the verdicts by scenario?
Launching an independent online pharmacy on Shopify or a custom build. Shortlist Mollie plus one specialist. Apply the filter and the written questions to both, and add PayPal by pre-approval once the card rail is running.
Established community pharmacy adding online sales. Start with your existing acquirer, which already banks the business. Benchmark its card-not-present quote against a PSP before signing — incumbency is a convenience, not a price.
Subscription-heavy treatment-plan model. Weight the decision towards MIT mechanics, dispute tooling and token portability. That favours the specialist tier, and the enterprise platforms as scale increases. Test whichever provider you choose against the recurring-billing questions verbatim.
Higher-risk product mix or post-termination rebuild. The onshore specialists, with contract-clause review treated as non-negotiable.
Scaled group. Take two genuine months of statements to the enterprise tier and negotiate.
Every scenario ends the same way. Whatever this article puts on your shortlist, the provider's written acceptance of your pharmacy, your mix and your volumes is the only sentence that binds anyone. The launch timeline should schedule obtaining it among the first tasks, not the last.
Key takeaways
- Named lists map the field; they do not grant accounts. Acceptance is per merchant, stances are dated 27 July 2026, and written confirmation for your specific mix outranks every sentence here.
- Mollie is the strongest typical first shortlist entry in mid-2026: pharmacy onboarding with enhanced documentation, modern integrations, recurring tooling and per-merchant approval — subject to the noted disclosure that this site's publisher is a partner.
- PayPal works as a conversion-lifting wallet after pre-approval under its Acceptable Use Policy — and as an account limitation waiting to happen without it. Backbone first, button second.
- Stripe is viable only with explicit written category acceptance. Its self-serve onboarding and pharmacy's underwriting requirements are a structural mismatch, and softened descriptions break this cluster's first rule.
- Traditional acquirers offer bank-grade substance through full underwriting. Onshore specialists legitimately serve harder mixes at candid prices. Enterprise platforms are the destination negotiation volume earns.
- BNPL, offshore brokers and crypto gateways are excluded deliberately — on ethical, risk and principled grounds respectively.
- Whatever the shortlist: apply the filter first, put ten questions in writing, work out effective rates, review the contract clauses, and schedule the payments file at the start of the launch plan.
Sources and further reading
FAQs
Checkouts we build every week.
Our publisher integrates pharmacy checkouts across the providers in this article, Mollie included. That means documentation packs that get pharmacy applications approved, recurring billing wired correctly, and orders flowing into Dataforge PMR. If you want the shortlist turned into a live, compliant checkout, see how it works.
See Dataforge PMR